相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Current insights and future prospects for the pathogenesis and treatment for rheumatoid arthritis
Tomohiro Koga et al.
CLINICAL IMMUNOLOGY (2021)
Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients in Sustained Remission
Jeffrey R. Curtis et al.
ARTHRITIS & RHEUMATOLOGY (2021)
Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial
Bernard Combe et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Radiographic and clinical outcomes following etanercept monotherapy in Japanese methotrexate-naive patients with active rheumatoid arthritis
Tsutomu Takeuchi et al.
MODERN RHEUMATOLOGY (2020)
Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial
Merete Lund Hetland et al.
BMJ-BRITISH MEDICAL JOURNAL (2020)
Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial
Emilie Ducourau et al.
RMD OPEN (2020)
Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies
Mark C. Genovese et al.
ARTHRITIS RESEARCH & THERAPY (2020)
Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study
Jacques-Eric Gottenberg et al.
BMJ-BRITISH MEDICAL JOURNAL (2019)
Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial
Roy Fleischmann et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Eight-year survival study of first-line tumour necrosis factor α inhibitors in rheumatoid arthritis: real-world data from a university centre registry
Christos G. Papadopoulos et al.
RHEUMATOLOGY ADVANCES IN PRACTICE (2019)
Lethal disseminated tuberculosis in patients under biological treatment - two clinical cases and a short review
Elena Dantes et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2018)
Rapid onset of efficacy predicts response to therapy with certolizumab plus methotrexate in patients with active rheumatoid arthritis
Young Mo Kang et al.
KOREAN JOURNAL OF INTERNAL MEDICINE (2018)
Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naive patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study
P. Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
Peter C. Taylor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Maintenance of remission with combination etanercept-DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access
Karel Pavelka et al.
RHEUMATOLOGY INTERNATIONAL (2017)
Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis
Jose Ramon Maneiro et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2017)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression
Tatsuya Atsumi et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis
Ronald F. van Vollenhoven et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy
Zhanguo Li et al.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2016)
Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity-results from the ENCOURAGE study, a prospective, international, multicenter randomized study
Hisashi Yamanaka et al.
MODERN RHEUMATOLOGY (2016)
Two-year radiographic and clinical outcomes from the Canadian Methotrexate and Etanercept Outcome study in patients with rheumatoid arthritis
Edward C. Keystone et al.
RHEUMATOLOGY (2016)
Two Dosing Regimens of Certolizumab Pegol in Patients With Active Rheumatoid Arthritis
D. E. Furst et al.
ARTHRITIS CARE & RESEARCH (2015)
Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial
J. S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study
Tsutomu Takeuchi et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial
Kim Horslev-Petersen et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial
J. L. Nam et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase
Michael H. Schiff et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
TNF-α Gene Polymorphisms: Association with Disease Susceptibility and Response to Anti-TNF-α Treatment in Psoriatic Arthritis
Giuseppe Murdaca et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial
Kazuhiko Yamamoto et al.
MODERN RHEUMATOLOGY (2014)
Sustained Remission with Etanercept Tapering in Early Rheumatoid Arthritis
Paul Emery et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study)
William P. Kennedy et al.
ARTHRITIS RESEARCH & THERAPY (2014)
Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study)
Marjatta Leirisalo-Repo et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial
Michael E. Weinblatt et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24weeks
Tsutomu Takeuchi et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study
Jacqueline Detert et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study
Arthur Kavanaugh et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
A Clinical Trial and Extension Study of Infliximab in Korean Patients with Active Rheumatoid Arthritis despite Methotrexate Treatment
Jinhyun Kim et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2013)
A phase 3 randomized, double-blind, multicenter comparative study evaluating the effect of etanercept versus methotrexate on radiographic outcomes, disease activity, and safety in Japanese subjects with active rheumatoid arthritis
Tsutomu Takeuchi et al.
MODERN RHEUMATOLOGY (2013)
Free radicals and endothelial dysfunction: Potential positive effects of TNF-α inhibitors
Giuseppe Murdaca et al.
REDOX REPORT (2013)
Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study
Yoshiya Tanaka et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Randomized comparison of etanercept with usual therapy in an Asian population with active rheumatoid arthritis: the APPEAL trial
Ho-Youn Kim et al.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2012)
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
Ronald F. van Vollenhoven et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX
Ernest Choy et al.
RHEUMATOLOGY (2012)
Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study
Michael E. Weinblatt et al.
RHEUMATOLOGY (2012)
A randomised efficacy and discontinuation study of etanercept versus adalimumab (RED SEA) for rheumatoid arthritis: a pragmatic, unblinded, non-inferiority study of first TNF inhibitor use: outcomes over 2 years
Paresh Jobanputra et al.
BMJ OPEN (2012)
Continuation of Methotrexate Resulted in Better Clinical and Radiographic Outcomes Than Discontinuation upon Starting Etanercept in Patients with Rheumatoid Arthritis: 52-week Results from the JESMR Study
Hideto Kameda et al.
JOURNAL OF RHEUMATOLOGY (2011)
Interpreting Indirect Treatment Comparisons and Network Meta-Analysis for Health-Care Decision Making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1
Jeroen P. Jansen et al.
VALUE IN HEALTH (2011)
Golimumab, a New Human Anti-Tumor Necrosis Factor α Antibody, Administered Intravenously in Patients With Active Rheumatoid Arthritis Forty-Eight-Week Efficacy and Safety Results of a Phase III Randomized, Double-Blind, Placebo-Controlled Study
Joel Kremer et al.
ARTHRITIS AND RHEUMATISM (2010)
Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial
J. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study
R. Fleischmann et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study
E. C. Keystone et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Golimumab, a Human Anti-Tumor Necrosis Factor α Monoclonal Antibody, Injected Subcutaneously Every Four Weeks in Methotrexate-Naive Patients With Active Rheumatoid Arthritis Twenty-Four-Week Results of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Golimumab Before Methotrexate as First-Line Therapy for Early-Onset Rheumatoid Arthritis
Paul Emery et al.
ARTHRITIS AND RHEUMATISM (2009)
Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate
M. Schiff et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Effect of the Early Use of the Anti-Tumor Necrosis Factor Adalimumab on the Prevention of Job Loss in Patients With Early Rheumatoid Arthritis
Victoria Bejarano et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2008)
Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate
Jonathan Kay et al.
ARTHRITIS AND RHEUMATISM (2008)
Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study
Nobuyuki Miyasaka
MODERN RHEUMATOLOGY (2008)
Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis
D. van der Heijde et al.
ARTHRITIS AND RHEUMATISM (2007)
A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases
Michael H. Weisman et al.
RHEUMATOLOGY (2007)
Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study
P. L. C. M. van Riel et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies - Systematic review and meta-analysis of rare harmful effects in randomized controlled trials
T Bongartz et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities - A large, randomized, placebo-controlled trial
R Westhovens et al.
ARTHRITIS AND RHEUMATISM (2006)
The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
FC Breedveld et al.
ARTHRITIS AND RHEUMATISM (2006)
Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy - A randomized, placebo-controlled, 52-week trial
EC Keystone et al.
ARTHRITIS AND RHEUMATISM (2004)
Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate
RN Maini et al.
ARTHRITIS AND RHEUMATISM (2004)
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis - A randomized, controlled trial
EWS Clair et al.
ARTHRITIS AND RHEUMATISM (2004)
Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed
BA van de Putte et al.
ANNALS OF THE RHEUMATIC DISEASES (2004)
Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate - The ARMADA trial
ME Weinblatt et al.
ARTHRITIS AND RHEUMATISM (2003)
Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study
LBA van de Putte et al.
ANNALS OF THE RHEUMATIC DISEASES (2003)
Etanercept versus methotrexate in patients with early rheumatoid arthritis - Two-year radiographic and clinical outcomes
MC Genovese et al.
ARTHRITIS AND RHEUMATISM (2002)
分享论文
